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Abstract
Background: Liver injury due to dengue viral infection is not uncommon. Acute liver injury is a severe complicating 
factor in dengue, predisposing to life-threatening hemorrhage, Disseminated Intravascular Coagulation (DIC) and 
encephalopathy. Therefore we sought to determine the frequency of hepatitis in dengue infection and to compare the 
outcome (length of stay, in hospital mortality, complications) between patients of Dengue who have mild/moderate 
(ALT 23-300 IU/L) v/s severe acute hepatitis (ALT > 300 IU/L).
Methods: A Cohort study of inpatients with dengue viral infection done at Aga Khan University Hospital Karachi. All 
patients (≥ 14 yrs age) admitted with diagnosis of Dengue Fever (DF), Dengue Hemorrhagic Fever (DHF) or Dengue 
Shock Syndrome (DSS) were included. Chi square test was used to compare categorical variables and fischer exact test 
where applicable. Survival analysis (Cox regression and log rank) for primary outcome was done. Student t test was 
used to compare continuous variables. A p value of less than or equal to 0.05 was taken as significant.
Results: Six hundred and ninety nine patients were enrolled, including 87% (605) patients with DF and 13% (94) 
patients with DHF or DSS. Liver functions tests showed median ALT of 88.50 IU/L; IQR 43.25-188 IU/L, median AST of 174 
IU/L; IQR 87-371.5 IU/L and median T.Bil of 0.8 mg/dl; IQR 0.6-1.3 mg/dl. Seventy one percent (496) had mild to 
moderate hepatitis and 15% (103) had severe hepatitis. Mean length of stay (LOS) in patients with mild/moderate 
hepatitis was 3.63 days v.s 4.3 days in those with severe hepatitis (P value 0.002). Overall mortality was 33.3% (n = 6) in 
mild/moderate hepatitis vs 66.7% (n = 12) in severe hepatitis group (p value < 0.001). Cox regression analysis also 
showed significantly higher mortality in severe hepatitis group (H.R (4.91; 95% CI 1.74-13.87 and P value 0.003) and in 
DHF/DSS (5.43; CI 1.86-15.84 and P value 0.002). There was a significant difference for the complications like Bleeding (P 
value < 0.001), Acute Renal failure (ARF) (P value 0.002), Acalculus cholecystitis (P value 0.04) and encephalopathy (P 
value 0.02) in mild/moderate and Severe hepatitis groups respectively.
Conclusion: Severe hepatitis (SGPT>300IU) in Dengue is associated with prolonged LOS, mortality, bleeding and RF.
Background
Dengue fever is an arboviral infection transmitted by
Aedes ageptyi as well as Aedes Albopictus and causes 4
spectra of illness which are an asymptomatic phase, acute
febrile illness, classic Dengue fever (DF), Dengue Hemor-
rhagic Fever (DHF) which includes Dengue Shock Syn-
drome (DSS) [1-3]. Dengue viral infection has been
recognized as one of the world's biggest emerging epi-
demic. Throughout the tropics this infection has an
annual incidence of 100 million cases of DF with another
250,000 cases of DHF and mortality rate of 24,000-25,000
per year[1,4,5]. Most of these cases are reported from
South East Asian areas which are most favorite tourist's
point[4,6]. In Pakistan at least two confirmed outbreaks
have been reported first in 1994 and second in 2005.
Since then we are continuously facing the problem of an
epidemic each year in Karachi and some other areas of
Pakistan [7,8]. During the last couple of years Pakistan
has become an endemic region as this virus is being
transmitted westward from India[7].
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when liver and nervous system are involved simultane-
ously by dengue[9]. Atypical manifestations include liver
involvement, central nervous involvement (encephalopa-
thy) and cardiac alterations in DF. None of the studies
have reported about the severity of liver involvement in
Dengue fever with reference to mortality and Length of
Stay (LOS). Liver involvement in dengue fever is mani-
fested by the elevation of transaminases representing
reactive hepatitis. This has been recognized over the last
two decades during the recent epidemics in Brazil[10]. A
study from Thialand (Retrospective review) has reported
34.6% liver dysfunction in pediatric population infected
with dengue[11]. Elevated transaminases in DF are due to
many conditions like use of hepatotoxic drugs and direct
attack of virus itself causing these unusual clinical mani-
festations. These in turn lead to more serious fate among
the dengue patients [10,12].
The involvement of liver in dengue fever is not uncom-
mon as reported in literature since 1970[13]. In the Liver
Function Tests (LFT) most common abnormality seen is
elevated transaminases which are involved in amino acid
metabolism. In approximately 90% of the patients with
DF, Aspartate Aminotransferase (AST) is higher than the
Alanine Aminotransferase (ALT) [14,15]. DF initiates the
inflammatory responses leading to liver parenchymal
changes and causing release of transaminases in circula-
tion[16]. Since DF is an emerging infection in Pakistan
and very little is known about the severity of hepatitis and
their outcome in patients with dengue fever when liver is
involved. Therefore we aim to assess the frequency of
hepatitis in dengue infection. We also aim to compare
their outcome (mortality, length of stay and complica-
tions) between patients with mild to moderate and severe
hepatitis in dengue infection.
Methods
We conducted a cohort study on inpatients with dengue
fever at Aga Khan University Hospital Karachi Pakistan
(AKUH). All patients were uniformly tested on day of
admission using a standardized protocols being used in
hospital for patients with dengue infection. We selected a
cohort of patients with hepatitis from these patients with
dengue infection. AKUH is part of Aga Khan Develop-
ment Network aimed at providing high quality of health
care, teaching and research. This University Hospital has
542 beds in operation and provides services to over
38,000 hospitalized patients and to over 500,000 outpa-
tients annually with the help of professional staff and
facilities that are among the best in the region.
Ethical clearance was taken from the institutional Ethi-
cal Review Committee (ERC). All inpatients of age ≥ 14
years who had history of acute fever, positive dengue IgM
and whose ALT were done, were included in the study.
We had excluded all those patients who had underlying
Chronic Liver Disease (CLD) or known positive serology
for viral hepatitis (HBsAg or HCVAb; n = 6) and those
patients who had malaria.
We divided this cohort of dengue inpatients with hepa-
titis into two groups based on ALT level; Mild (upto 5
times normal) to Moderate (5- 10 times) acute hepatitis:
ALT 23-300 IU/L, severe acute hepatitis: ALT > 300 IU/L
or ≥ 10 times [10,17-21]. Primary outcome measures
were mortality and LOS. Secondary outcome measures
were different complications; defined as; a) Bleeding was
defined as either mucosal bleeding (epistaxis or gum
bleed) or Gastrointestinal (GI) bleed; b). Acute Renal
Failure (ARF) was defined as rise of creatinine (Cr) >3
times of normal [22]; c) Encephalopathy was defined as
altered mental status (drowsiness, lethargy, agitation, or
coma) for ≥ 8 hours [23]; d) Shock was defined as systolic
pressure < 90 mm Hg [24]; e) Acalculous cholecystitis
was defined as inflammation of gall bladder without
stone on ultrasound[2]. We also dichotomized the data
based on diagnosis into DF and DHF/DSS for the primary
outcome measures (mortality and LOS) [25].
We required a minimum sample size of 350 patients by
assuming 35% prevalence of liver dysfunction in patients
with dengue fever, with 0.05 bound on error(precision)
and 95% confidence level[11].
Data was collected on predesigned proforma which
included demographics, clinical presentation, laboratory
parameters and outcome (in hospital mortality, length of
stay and complications). We included all patients who ful-
filled inclusion criteria and were admitted in the medical
ward through emergency room or clinic. Informed con-
sent was taken from patients. Proforma was filled for
each patient. Each patient was categorized either into
mild to moderate or severe hepatitis groups based on
ALT levels and these patients were followed for their out-
come till the end of inpatient stay.
Statistical analysis
Statistical Package for Social Sciences (SPSS) version 16
was used for analysis. Results are presented as mean ±
standard deviation (SD) for continuous variables, fre-
quency and percentage are given for qualitative variables.
For non normally distributed quantitative variables
median and Inter Quartile Ranges (IQR) were used. Chi
square test was used to compare categorical variables and
fischer exact test were used when numbers were too
small to perform the chi-square testing. Student t test was
used to compare continuous variables. In survival analy-
sis cox proportion hazard ratio (Cox regression) was
determined for mortality in DHF/DSS and severe hepati-
tis after fulfilling the assumption of proportional hazard
ratio. Kaplan Meir plot of survival over time and log rank
test were also used. A p value of ≤ 0.05 was taken as sig-
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calculated and 95% CI for death rate ratio were also cal-
culated.
Results
Total of 699 patients with DF were included, among them
65% were male. Mean age of patients was 31.87 ± 13.55
years. Approximately 86% (n = 604) were admitted with
DF, 12% were admitted with DHF and only 2% had DSS.
Malarial parasite was negative in all patients. Mean dura-
tion of fever was 6 ± 3.27 days with mean temperature of
38.5 ± 1°C. Among clinical features, 48.6% had nausea/
vomiting, 18.2% had abdominal pain, 17% had rash, 16%
had body ache, 10% had diarrhea, 9% had cough, 5.4% had
hematemesis, 5.2% had bleeding gum,4.3% had
malena,4% had altered mental status and 3.1% had jaun-
dice. On abdominal examination, 7% had right hypo-
chondric tenderness and 1.4% had epigastric tenderness.
In hemodynamics, mean pulse was 96 ± 18.5 beats/min,
mean systolic blood pressure was 113 ± 16 mmHg with
mean diastolic blood pressure of 71 ± 11 mmHg. The
complete blood count showed mean hemoglobin of 13.71
± 2.37 gm/l, mean hematocrit of 40.07 ± 6.8%, mean
white blood cell count of 5.5 ± 5/cmm and median plate-
let count of 48/cmm;IQR 23-96/cmm. Mean Activated
Partial Thromboplastin Time (APTT) was 36.34 ± 11.56
seconds with control of 40 seconds. Mean Cr was 1.12 ± 1
mg/dl. Liver function tests (LFTs) show the median ALT
of 88.50 IU/L; IQR 43.25-188 IU/L, median AST of 174
IU/L; IQR 87-371.5 IU/L, median ALK.Phos 80 IU/L;
IQR 54-129 IU/L and median T.Bil of 0.8 mg/dl; IQR 0.6-
1.3 mg/dl. Almost 86% (599) of the patients had elevated
ALT (hepatitis). The mean LOS was 3.88 ± 2.7 days in this
population. Mortality was 2.7% in our study. Among
complications, we have found 1.7% bleeding, 1.3% shock,
2.7% ARF 3.9% acalculous cholecystitis and 2.9% enceph-
alopathy.
Severe hepatitis was present in 15% and mild to moder-
ate hepatitis in 71% while 14% had normal ALT. Patients
with normal ALT were excluded from further analysis.
Overall mortality (n = 18) was significantly higher in
severe hepatitis group (66.70%;n = 12) as compared to
mild to moderate hepatitis (33.30%;n = 6). The survival
probability of mild to moderate and severe hepatitis
group according to Kaplan-Meir curve is shown figure 1
with numbers at risk below the figure. Differences in
overall survival between these two groups is significant (P
value < 0.005; log rank). Mean length of stay in patients
with mild/moderate hepatitis was 3.63 days versus 4.3
days in those with severe hepatitis (figure 2). Cox regres-
sion (survival analysis) also showed the significantly
higher mortality in severe hepatitis group (H.R 4.91; 95%
CI 1.74-13.87 and P value 0.003) and DHF/DSS group
(H.R 5.43; CI 1.86-15.84 and P value 0.002) with reference
to mild to moderate hepatitis and DF respectively. Sub-
group analysis of DF and DHF/DSS for mortality has
shown significantly higher mortality in severe hepatitis
group versus mild to moderate hepatitis (3/436 versus 3/
81, P value 0.04 in DF; 3/60 versus 9/22, p value < 0.001 in
DHF/DSS group respectively). Comparison of subgroups
DF and DHF/DSS with reference to outcome is shown in
table 1. Comparison of secondary outcome measures is
shown in table 2.
Discussion
We report the largest cohort study from south Asia (Paki-
stan) on hepatitis in dengue fever patients and their asso-
ciation with outcome. Currently dengue is perhaps the
most common rapidly emerging viral infection through-
out the world and Pakistan reported its first outbreak in
1994[26].
Deranged liver functions are common in patients with
dengue infection due to direct attack on liver cells or
unregulated host immune response against the virus [19].
Hence measurement of AST and ALT are mandatory to
see the liver involvement [10]. We have found in our
study that deranged liver functions are an important fea-
ture in patients with dengue infection. Almost 86% of the
Table 1: Primary outcome measures according to severity of hepatitis within two categories diagnosis
Diagnosis Categories Severity of hepatitis Deaths n Death rate 
(Deaths/10 day)





LOS ± SD P value
Dengue fever (n = 517) Mild to Moderate 
Hepatitis (n = 436)
3 0.019 2.97(0.48,18.6) 0.283 3.50 ± 1.54 <0.025
Severe hepatitis (n = 81) 3 0.093 3.96 ± 2.27
DHF/DSS
(n = 82)
Mild to Moderate 
Hepatitis (n = 60)
3 0.010 5(1.3,16) 0.003 4.60 ± 2.87 .212
Severe hepatitis (n = 22) 9 0.073 5.60 ± 3.85
^H.R = Hazard Ratio, UCI = Upper confidence interval, LCI = Lower confidence interval
! Log Rank value
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95% patients had elevated AST. However Wong et al
reported that AST abnormality was predominantly
higher as compared to ALT; 91% and 72% respectively,
which is consistent with our study. However we report
higher values of AST and ALT in our study population
than reported by Wong et al and other studies
[10,19,27,28]. Souza et al also reported the similar trend
of AST/ALT in dengue fever but with much lower level as
compared to our population[10]. This difference can be
explained on the basis that in our study all patients were
inpatients while in their study all the patients were outpa-
tients with less severe disease. Furthermore a study from
Asia pacific region (Taiwan) by Kuo et al has shown
approximately 90% of the AST abnormality in dengue
patients which is consistent with our study[29]. We can
assume that reasons for higher ALT or AST levels in our
population are either due to more virulent strain of den-
gue infection or virus is more hepatotoxic. Therefore fur-
ther studies are required to highlight the possible
hepatotropic nature of this virus as well as virulence and
type of virus.
Immune responses including the innate and acquired;
play important role in determining the response to any
virus. Causation of the severity dengue infection has been
explained by the hypothesis of immune enhancement and
virulence nature of virus [21]. Chaturvedi et al in their
study detected the appearance of different helper cells
cytokines in human white blood cells cultures infected in
vitro with dengue virus type 2. In their study they have
reported that during dengue infection; monocytes, B
cells, T cells and mast cells produce large amounts of
cytokines [30]. Based on this we can hypothesize the sim-
ilar mechanism responsible for hepatoxicity in our study
population. Despite all this, role of host immunity in den-
gue infection is still very unclear. Dengue antigens have
been identified within the liver parenchyma on postmor-
tem of these patients hence virus seems to be able to rep-
licate within the hepatocytes. Unregulated host immune
response may play some part in severity of dengue infec-
tion therefore by modifying the immune response, severe
infection can be prevented [21].
We have seen significantly higher mortality in patients
with severe hepatitis. We report 2.7% mortality in our
study population. Similar mortality figure (2.6%)was
reported in an earlier study from Pakistan but with a
smaller sample size (n = 225)[31]. Literature regarding
Table 2: Complications in two groups of severity of hepatitis
Complications Mild to moderate (n = 496) Severe hepatitis (n = 103) P value
Bleeding1 (n) 3 7 <0.0016
Renal failure2 (n) 8 8 0.002
Encephalopathy3 (n) 7 11 0.02
Shock4 (n) 6 2 0.406
Acalculus cholecystitis5 (n) 14 7 0.04
1. Either mucosal bleeding (epistaxis or gum bleed) or Gastrointestinal (GI) bleed
2. Acute Renal Failure (ARF) was defined as rise of creatinie >3 times(13)
3. Encephalopathy was defined as altered mental status for > 8 hours (drowsiness, lethargy, agitation, or coma)(19)
4. Shock was defined as Hypotension (defined as systolic pressure < 90 mm Hg)(14)
5. Acalculus cholecystitis was defined as inflammation of gall bladder without stone on US (15)
6. Anayzed by fischer exact test
Figure 1 Kaplan-Meir curve of survival over time in two groups of 
patients with hepatitis.
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function is scarce. Nguyen TL et al concluded in their
study on 45 patients in Vietnam, that DHF may cause
mild to moderate liver dysfunction in most cases; only
some patients may suffer from acute liver failure leading
to encephalopathy and death [9]. However liver involve-
ment was not studied with reference to mortality. Shah
has reported high mortality in dengue patients with hep-
atitis and encephalopathy[32]. However this was a small
study from India, done on 4 pediatric patients only. Our
study is the first large study from South Asia region, to
highlight the mortality with deranged liver function in
dengue patients. The self limiting clinical course of den-
gue infection can be prolonged when the liver is involved
as suggested by Souza et al[10]. Hence we have seen
worse prognosis in terms of mortality and length of stay
Figure 2 Box plot showing length of stay (in days) in two groups of severity of hepatitis.
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involvement. On further subgroup analysis we also saw
that mortality was significantly higher in severe category
of hepatitis in both DF and DSS. We can postulate that
severe hepatitis may be a significant contributing factor
to mortality in patients with dengue infection. However
further immunologic studies need to be done to establish
the cause of liver involvement; whether it is due to virus
itself or due to immunologic reaction (reactive hepatitis).
The mean length of stay was approximately 4 days in
our study population with dengue infection while a study
from Singapore by Lye et al[33] had reported mean LOS
of 3 days. Khan et al reported in their study (166 patients)
in Saudi population; that median duration of hospital stay
was 4 days in dengue patients but there was no compari-
son based on liver functions [34]. No study has reported
LOS in comparison with liver involvement as yet. Severe
hepatitis in dengue fever does affect the LOS when the
disease is mild (DF) but as disease become more severe,
severe hepatitis does not affect the LOS.
We have found that clinical complications like bleeding,
renal failure, encephalopathy and Acalculous cholecysti-
tis were higher in those who had severe hepatitis. A study
from Saudi population by Khan et al had made an associ-
ation between high AST level with these complica-
tion[34]. But we have seen the complications with
reference to hepatitis based on serum ALT levels. We
have seen significantly higher bleeding complication in
patients with severe hepatitis. Similarly Kuo CH et al has
reported higher bleeding episodes in those who had high
levels of AST, ALT and GGT[29]. An other study has also
reported significantly higher spontaneous bleeding epi-
sodes in patients with elevated ALT and Alk.Phos [27].
Nguyen TL et al has also found significantly higher eleva-
tion of AST and ALT in DHF patients with gastrointesti-
nal haemorrhage [9]. We can postulate that deranged
liver functions may have a significant role in bleeding in
addition to thrombocytopenia. We have found signifi-
cantly higher proportion of patients with renal failure
who had severe hepatitis. There are case reports of acute
renal failure/injury in dengue fever in the literature, but
none of them have been studied along with liver involve-
ment in adults[35]. Encephalopathy in our study popula-
tion was also significantly higher in the severe hepatitis
group. There are case reports available regarding the
encephalopathy in dengue infection in adult popula-
tion[36]. However encephalopathy is well studied in pedi-
atric population[37]. Acalculous cholecystitis was
significantly high in the patients with severe hepatitis.
Acalculous cholecystitis is very known entity among
patients with dengue fever but none of them have shown
comparison according to severity of hepatitis[38,39].
Three percent of the patients had jaundice in our study
population. Larreal Y et al has reported jaundice in only 2
out of 63 patients in their study on hepatic alteration in
dengue fever [40].
Strength and Limitations
This is the largest study from South Asia on patients with
dengue fever. This is the first study which is comparing
the outcome in dengue patients with hepatitis.
This study has limited external validity since this is
study of inpatients and has not included patients who
have visited outpatient and other hospitals in the city.
The study population in our tertiary care hospital is from
middle to high income population which comprises only
small percentage of city population. We also did not
check for the type of dengue virus.
Conclusion
We conclude that majority of the patients with dengue
infection have hepatitis. Severe hepatitis in dengue infec-
tion has got worse outcome in terms of length of stay,
mortality and complications as compared to mild to
moderate hepatitis. Therefore severe hepatitis can be
considered as a bad prognostic indicator of outcome in
dengue infection. Though majority of the patients had
self resolving course of illness but they can be potential
candidate for acute fulminant hepatic failure. Dengue
fever should be considered when liver functions are
deranged apart from routine hepatotropic viruses. Fur-
ther studies are required to establish the fact whether
liver injury is due to hepatotropic nature of the virus or
due to immunologic injury.
New to knowledge
Outcome of dengue fever when there is an involvement of
abnormal liver functions.
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